Boccafoschi C, Montefiore F, Pavesi M, Pastormerlo M, Betta P G
Division of Urology, City Hospital, Alessandria, Italy.
Eur Urol. 1995;27(4):334-8. doi: 10.1159/000475192.
During intravesical bacillus Calmette-Guérin (BCG) treatment for the prophylaxis of recurrent superficial bladder carcinoma, patients typically show a local inflammatory response involving mainly T lymphocytes, most of which have the helper-induced phenotype (CD4+) (CD4+/CD8+ ratio > 1). To evaluate whether this immunophenotypic profile of the lymphocytes persists also after the completion of this immunotherapy, we examined bladder biopsy specimens during the posttreatment follow-up period of 24 patients, previously submitted to a 2-year BCG administration. The intensity of inflammatory response differed among the patients and in 10 of them even between the scar and the normal mucosa of the bladder. A reversal to the pretreatment CD4+/CD8+ ratio < 1 occurred in the majority of subjects, including the 3 patients with histologically confirmed tumour recurrence. In addition, 11 tumour-free patients showed prevailing CD4+ cells in the scar mucosa and prevailing CD8+ in the normal mucosa of their bladder or vice versa. From these findings it appears that the long-term host response to BCG does not depend exclusively on an intense, long-lasting local mononuclear immune reaction.
在采用卡介苗(BCG)膀胱内灌注预防复发性浅表性膀胱癌的过程中,患者通常会出现以T淋巴细胞为主的局部炎症反应,其中大多数T淋巴细胞具有辅助诱导型表型(CD4+)(CD4+/CD8+比率>1)。为了评估这种淋巴细胞免疫表型在这种免疫治疗结束后是否依然持续存在,我们检查了24例患者在治疗后随访期间的膀胱活检标本,这些患者此前接受了为期2年的BCG灌注治疗。患者之间炎症反应的强度有所不同,其中10例患者膀胱瘢痕组织与正常黏膜之间的炎症反应强度也存在差异。大多数受试者,包括3例经组织学证实肿瘤复发的患者,其CD4+/CD8+比率恢复到治疗前的<1。此外,11例无肿瘤患者膀胱瘢痕黏膜中CD4+细胞占优势,正常黏膜中CD8+细胞占优势,或者情况相反。从这些发现看来,宿主对BCG的长期反应并非完全取决于强烈且持久的局部单核免疫反应。